Curcumin as an anti-proliferative agent in breast cancer through RASSF1A, Bax, and caspase-3 protein
N. A. Rahmah,
H. Harliansyah,
F. D. Suyatna,
M. Kanoko,
P. Rustamadji,
J. Prihartono,
A. Bustami,
S. J. Haryono,
B. S. Hernowo https://doi.org/10.21294/1814-4861-2022-21-6-91-98
Abstract
Background. Curcumin is a polyphenol that has pharmacological activity that can inhibit tumor cell growth and induce apoptosis through various mechanisms. However, the specifc mechanism of curcumin cytotoxicity remains controversial because of many anti- and pro-apoptotic signaling pathways in various cell types.
This study aims to examine the relationship among curcumin on RASSF1A, Bax protein levels, and caspase-3 activity in supporting the apoptotic mechanism in CSA03 breast cancer cells.
Material and Methods. Curcumin administration to cancer cells is based on differences in dosage with 24-hour incubation. Cytotoxicity after curcumin administration was determined using MTS. RASSF1A and Bax protein levels were tested through ELISA. Caspase-3 activity was used to determine apoptosis and was tested using fow cytometry.
Results. The results indicated that curcumin had a cytotoxicity effect of 40.85 µg/mL. At concentrations of 40 µg/mL and 50 µg/mL, curcumin increases levels of protein RASSF1A (∆ = 26.53% and 47.35%, respectively), Bax (∆ = 48.79% and 386.15%), and caspase-3 (∆ = 1,678.51% and 1,871.889%) signifcantly.
Conclusions. Curcumin exhibits anti-proliferative activity and apoptotic (Caspase-3) effects through activation of RASSF1A and Bax.
About the Authors
N. A. Rahmah
Universitas YARSI
Indonesia
Indonesia
Nunung Ainur Rahmah, dr., Sp.PA, Department of anatomical pathology, Faculty of Medicine,
Jakarta, 10520
H. Harliansyah
Universitas YARSI
Indonesia
Indonesia
Harliansyah, M.Si., PhD, Department of biochemistry, Faculty of Medicine,
Jakarta, 10520
F. D. Suyatna
Universitas Indonesia
Indonesia
Indonesia
Franciscus D. Suyatna, Prof., dr., PhD., Sp.FK, Department of pharmacology, Faculty of Medicine,
Jakarta, 10440
M. Kanoko
Universitas Indonesia
Indonesia
Indonesia
Mpu Kanoko, Prof., dr., SpPA(K), PhD, Department of anatomical pathology, Faculty of Medicine,
Jakarta, 10440
P. Rustamadji
Universitas Indonesia
Indonesia
Indonesia
Primariadewi Rustamadji, Dr. dr., MM. SpPA(K), Department of anatomical pathology, Faculty of Medicine,
Jakarta, 10440
J. Prihartono
Universitas Indonesia
Indonesia
Indonesia
Joedo Prihartono, Dr. dr., MPH, Department of Public health, Faculty of Medicine,
Jakarta, 10440
A. Bustami
Universitas Indonesia
Indonesia
Indonesia
Arleni Bustami, MS. Ka, Department of Integrated laboratory, Faculty of Medicine,
Jakarta, 10440
S. J. Haryono
National Cancer Center Dharmais Hospital
Indonesia
Indonesia
Samuel Johny Haryono, Dr. dr., Sp.B (K)Onk, Department of oncology,
Jakarta, 11420
B. S. Hernowo
Universitas Padjajaran
Indonesia
Indonesia
Hj. Bethy S. Hernowo, Prof., dr., Sp.PA(K), PhD, Department of anatomical pathology, Faculty of Medicine,
Bandung, 45363
References
1. 1.World Health Organization. Breast cancer-WHO [Internet]. URL: https://www.who.int/news-room/fact-sheets/detail/breast-cancer [cited 2022 Jul 22].
2. Kanker di Indonesia tahun 2010: Data Histopatologik. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia dan Yayasan Kanker Indonesia.
3. Abdulkareem I.H., Zurmi I.B. Review of hormonal treatment of breast cancer. Niger J Clin Pract. 2012; 15(1): 9–14. doi: 10.4103/1119- 3077.94088.
4. Thuy L.H.A., Thuan L.D., Phuong T.K. DNA hypermethylation in breast cancer. In: Pham PV, ed. (2017) Breast Cancer – From Biology to Medicine. London: InTech. 147–61. doi: 10.5772/66900.
5. Cao X., Tang Q., Holland-Letz T., Gündert M., Cuk K., Schott S., Heil J., Golatta M., Sohn C., Schneeweiss A., Burwinkel B. Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. Int J Mol Sci. 2018; 19(3): 900. doi: 10.3390/ijms19030900.
6. Law J., Salla M., Zare A., Wong Y., Luong L., Volodko N., Svystun O., Flood K., Lim J., Sung M., Dyck J.R., Tan C.T., Su Y.C., Yu V.C., Mackey J., Baksh S. Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein. J Biol Chem. 2015; 290(40): 24100–18. doi: 10.1074/jbc.M115.648345.
7. Howell P.M., Liu Z., Khong H.T. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals (Basel). 2010; 3(7): 2022–44. doi: 10.3390/ph3072022.
8. Foulks J.M., Parnell K.M., Nix R.N., Chau S., Swierczek K., Saunders M., Wright K., Hendrickson T.F., Ho K.K., McCullar M.V., Kanner S.B. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen. 2012; 17(1): 2–17. doi: 10.1177/1087057111421212.
9. Goel A., Aggarwal B.B. Curcumin, the golden spice from Indian safron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010; 62(7): 919–30. doi: 10.1080/01635581.2010.509835.
10. Basnet P., Skalko-Basnet N. Curcumin: an anti-infammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011; 16(6): 4567–98. doi: 10.3390/molecules16064567.
11. Khazaei Koohpar Z., Entezari M., Movafagh A., Hashemi M. Anticancer Activity of Curcumin on Human Breast Adenocarcinoma: Role of Mcl-1 Gene. Iran J Cancer Prev. 2015; 8(3). doi: 10.17795/ijcp2331.
12. Dai X., Cheng H., Bai Z., Li J. Breast Cancer Cell Line Classifcation and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017; 8(16): 3131–41. doi: 10.7150/jca.18457.
13. Rahmah N.A., Harliansyah H., Suyatna F.D., Kanoko M., Rustamadji P., Prihartono J., Haryono S.J., Hernowo B.S. The role of curcumin on apoptosis through the RASSF1A and Bax pathways in breast cancer. Indonesian Journal of Cancer Chemoprevention. 2020; 11(2): 67–74. doi: 10.14499/indonesianjcanchemoprev11iss2pp67-74.
14. Hafner M., Niepel M., Chung M., Sorger P.K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods. 2016; 13(6): 521–7. doi: 10.1038/nmeth.3853.
15. He Y., Zhu Q., Chen M., Huang Q., Wang W., Li Q., Huang Y., Di W. The changing 50 % inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. Oncotarget. 2016; 7(43): 70803–21. doi: 10.18632/oncotarget.12223.
16. Nicco C., Batteux F. ROS Modulator Molecules with Therapeutic Potential in Cancers Treatments. Molecules. 2017; 23(1): 84. doi: 10.3390/molecules23010084.
17. Skonieczna M., Hejmo T., Poterala-Hejmo A., Cieslar-Pobuda A., Buldak R.J. NADPH Oxidases: Insights into Selected Functions and Mechanisms of Action in Cancer and Stem Cells. Oxid Med Cell Longev. 2017. doi: 10.1155/2017/9420539.
18. Lv Z.D., Liu X.P., Zhao W.J., Dong Q., Li F.N., Wang H.B., Kong B. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol. 2014; 7(6): 2818–24.
19. Zhang Y., Cao H., Yu Z., Peng H.Y., Zhang C.J. Curcumin inhibits endometriosis endometrial cells by reducing estradiol production. Iran J Reprod Med. 2013; 11(5): 415–22.
20. Hagrass H.A., Pasha H.F., Shaheen M.A., Abdel Bary E.H., Kassem R. Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep. 2014; 41(1): 57–65. doi: 10.1007/s11033-013-2837-3.
21. Ung M., Ma X., Johnson K.C., Christensen B.C., Cheng C. Efect of estrogen receptor α binding on functional DNA methylation in breast cancer. Epigenetics. 2014; 9(4): 523–32. doi: 10.4161/epi.27688.
22. Cheng Y., Xie N., Jin P., Wang T. DNA methylation and hydroxymethylation in stem cells. Cell Biochem Funct. 2015; 33(4): 161–73. doi: 10.1002/cbf.3101.
23. Liu Z., Xie Z., Jones W., Pavlovicz R.E., Liu S., Yu J., Li P.K., Lin J., Fuchs J.R., Marcucci G., Li C., Chan K.K. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett. 2009; 19(3): 706–9. doi: 10.1016/j.bmcl.2008.12.041.
Review
For citations:
Rahmah N.A., Harliansyah H., Suyatna F.D., Kanoko M., Rustamadji P., Prihartono J., Bustami A., Haryono S.J., Hernowo B.S. Curcumin as an anti-proliferative agent in breast cancer through RASSF1A, Bax, and caspase-3 protein. Siberian journal of oncology. 2022;21(6):91-98. https://doi.org/10.21294/1814-4861-2022-21-6-91-98
Views:
1394
Email this article 
